Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Choroidal Neovascularization - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Choroidal Neovascularization - Pipeline Review, H2 2015', provides an overview of the Choroidal Neovascularization's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Choroidal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Choroidal Neovascularization and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Choroidal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Choroidal Neovascularization Overview 9 Therapeutics Development 10 Pipeline Products for Choroidal Neovascularization - Overview 10 Pipeline Products for Choroidal Neovascularization - Comparative Analysis 11 Choroidal Neovascularization - Therapeutics under Development by Companies 12 Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 13 Choroidal Neovascularization - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Choroidal Neovascularization - Products under Development by Companies 17 Choroidal Neovascularization - Products under Investigation by Universities/Institutes 18 Choroidal Neovascularization - Companies Involved in Therapeutics Development 19 Affitech A/S 19 Aprogen, Inc. 20 F. Hoffmann-La Roche Ltd. 21 Genentech, Inc. 22 Iconic Therapeutics, Inc. 23 Mabion SA 24 Navigen Pharmaceuticals, Inc. 25 Noxxon Pharma AG 26 Promedior, Inc. 27 Regeneron Pharmaceuticals, Inc. 28 Sanwa Kagaku Kenkyusho Co., Ltd. 29 Choroidal Neovascularization - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 aflibercept - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Antisense Oligonucleotides for Ophthalmology and Cancer - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AP-202 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Doxarubicin Pegylated - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 hI-con1 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 MAb-30D8 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NAV-2729 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Netrin-4 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 NM-9405 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 NOXD-20 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 PGN-635 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 PRM-167 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ranibizumab - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ranibizumab biosimilar - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Recombinant Protein for Choroidal Neovascularization - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 RG-7716 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 SK-1011 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Choroidal Neovascularization - Recent Pipeline Updates 66 Choroidal Neovascularization - Dormant Projects 82 Choroidal Neovascularization - Discontinued Products 84 Choroidal Neovascularization - Product Development Milestones 85 Featured News & Press Releases 85 Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 85 Mar 11, 2015: Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU 86 Nov 18, 2014: Intravitreal VEGF Inhibitor EYLEA Obtains Additional Indication of Diabetic Macular Edema, Its Fourth Indication 87 Sep 22, 2014: Regeneron Announces EYLEA (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization in Japan 88 Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 89 Nov 18, 2013: Data at 48 weeks for Phase 3 MYRROR trial in mCNV demonstrate long-term efficacy of VEGF Trap-Eye 89 Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 90 Jun 06, 2013: Regeneron And Bayer Report Positive Phase III Results For Eylea Injection In Myopic Choroidal Neovascularization 91 May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 92 Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection 93 Appendix 94 Methodology 94 Coverage 94 Secondary Research 94 Primary Research 94 Expert Panel Validation 94 Contact Us 94 Disclaimer 95
List of Tables
Number of Products under Development for Choroidal Neovascularization, H2 2015 10 Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2015 11 Number of Products under Development by Companies, H2 2015 12 Number of Products under Investigation by Universities/Institutes, H2 2015 13 Comparative Analysis by Late Stage Development, H2 2015 14 Comparative Analysis by Clinical Stage Development, H2 2015 15 Comparative Analysis by Early Stage Development, H2 2015 16 Products under Development by Companies, H2 2015 17 Products under Investigation by Universities/Institutes, H2 2015 18 Choroidal Neovascularization - Pipeline by Affitech A/S, H2 2015 19 Choroidal Neovascularization - Pipeline by Aprogen, Inc., H2 2015 20 Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 21 Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2015 22 Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H2 2015 23 Choroidal Neovascularization - Pipeline by Mabion SA, H2 2015 24 Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 25 Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2015 26 Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2015 27 Choroidal Neovascularization - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 28 Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015 29 Assessment by Monotherapy Products, H2 2015 30 Number of Products by Stage and Target, H2 2015 32 Number of Products by Stage and Mechanism of Action, H2 2015 34 Number of Products by Stage and Route of Administration, H2 2015 36 Number of Products by Stage and Molecule Type, H2 2015 38 Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H2 2015 66 Choroidal Neovascularization - Dormant Projects, H2 2015 82 Choroidal Neovascularization - Dormant Projects (Contd..1), H2 2015 83 Choroidal Neovascularization - Discontinued Products, H2 2015 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
